NHD Global
Cosmetic & Skin · Copper tripeptide research
Scientific Product Dossier
GHK-Cu is the copper complex of glycyl-L-histidyl-L-lysine, studied in extracellular-matrix and wound models. In a randomized topical study with 13 completers after CO2 laser resurfacing, objective assessments found no significant group difference in erythema, wrinkles or skin quality; a patient questionnaire favored GHK-Cu for perceived skin quality (p=0.04). Topical evidence does not support injectable claims.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
Among 13 completers, blinded and computer assessments found no significant GHK-Cu advantage for erythema, wrinkles or overall skin quality.
The questionnaire favored perceived skin quality at p=0.04; exploratory given the small sample.
Read the primary studyFDA flags potential aggregation, peptide-impurity and immunogenicity concerns for injectable GHK-Cu.
A topical study cannot close an injectable-route safety gap.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 50 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 100 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Miller TR, et al. Archives of Facial Plastic Surgery. 2006. PMID 16847171.
View primary recordU.S. FDA injectable GHK-Cu summary.
View primary recordThird-party publications selected for direct relevance.
Miller TR, et al. Archives of Facial Plastic Surgery. 2006. PMID 16847171.
U.S. FDA. Current compounding safety-information page.
Concise answers for researchers comparing identity, evidence and catalog variants.
Objective assessments found no significant group differences; one patient questionnaire favored perceived skin quality at p=0.04.
No. Route, formulation, exposure and sterility requirements are different.
Family-level identifiers organize the catalog, while the applicable product specification and lot-specific COA control the supplied form, identity and release results.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
The most directly relevant randomized topical GHK-Cu study was small: 13 patients completed it. Objective assessments did not find significant differences in erythema resolution,…
Updated August 28, 2026
Route is not a footnote in GHK-Cu evidence. A topical skin-care study and an injectable compounded preparation have different exposure, sterility, aggregation and safety…
Updated August 28, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: CU50 · 50 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
